EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

nDatalyze Corp (NDATF) fair value: what the stock is really worth

As of Sep 18, 2026: fair value of nDatalyze Corp $0.02, price $0.08, upside -70.0%, quality 41 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · Home Canada · ISIN CA63948H1055

NC nDatalyze Corp logo Thin data Sep 23, 2026

nDatalyze Corp

NDATF · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $0.0240 · Strongly overvalued (−70%)
!Quality 41/100
!Weak Growth (revenue 5y −68.2 %/yr)
!negative free cash flow
!Trails peers (0/6)
!Narrow moat 5/100
!Evidence only low, so the estimate is less certain
Watch nDatalyze Corp for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$0.2590 $0.0109 Fair Value $0.0240 Jul 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.

How to read this chart

60‑month range $0.0109 – $0.2590 · the $0.0800 price screens above the $0.0240 fair value. Dashed = 300-day average. As of Sep 23, 2026.

Follow nDatalyze in your weekly email

Every Wednesday you see whether nDatalyze is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

nDatalyze Corp. provides technologically based solutions related to applying machine learning to a records database to predict probable mental health conditions. It offers Sigmund, a machine-learning-based online mental health application for the mental health system, such as misdiagnosis and mis prescription.

Show more

nDatalyze Corp. provides technologically based solutions related to applying machine learning to a records database to predict probable mental health conditions. It offers Sigmund, a machine-learning-based online mental health application for the mental health system, such as misdiagnosis and mis prescription. The company was formerly known as MedXtractor Corp. and changed its name to nDatalyze Corp. in October 2021. nDatalyze Corp. was incorporated in 2018 and is headquartered in Calgary, Canada.

Stock analysis

nDatalyze Corp (NDATF) currently trades at $0.0800, while our model-based Fair Value estimate is $0.0240, implying the stock looks roughly 233.3% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 95/100, which puts the evidence level at low.

Quality & growth

The Quality Score stands at 41/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

nDatalyze Corp reported revenue of C$1.7K in FY2025 versus C$663K in FY2021, a compound −77.4%/yr. Reported net income was −C$554K in FY2025.

Key figures

Market cap $6.1M · Return on equity −59.8% · Return on assets (EBIT) −79.3% · Free cash flow −C$466K · Net cash C$794K.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 25 out of 100 (low confidence).

What moves the price

The share trades at its 52-week high and 634% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −45% fair-value upside, at −70%, NDATF screens richer than that median.

Fair Value models

Bear $0.0240 Fair Value $0.0240 Bull $0.0240
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.0100 $0.0100 $0.0100 53
All 1 models by family
Asset-Based
NCAV (Graham) $0.0100 $0.0100 $0.0100 53

Open the full fair value analysis →

Notify me when NDATF reaches fair value

Put NDATF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 41/100

Of which business quality 45 · Market factors (momentum, volatility) 78

Profitability 0
Margins and returns on capital today
Quality Growth 20
Are margins and returns improving?
Cashflow 31
Earnings quality: real cash, not paper profit
Fin. Strength 100
Balance sheet, leverage, solvency risk
Investment 100
Disciplined investing over empire-building
Low Volatility 50
Calm price path (market factor)
Momentum 83
Price trend over the last 3–12 months (market factor)
52W Momentum 100
Distance to the 52-week high (market factor)
Net Issuance 29
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−98.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−84.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−68.2%
Start year 2020 (pandemic)
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−53.2%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−8.5% (2020) → −37,220.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

NDATF screens 233% overvalued. Compare with Veeva Systems Inc →

Compare nDatalyze Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 133 stocks

Beats the industry median on 0/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 45 · Below median
Fair Value upside −70% · Bottom 25%
Profitability
Return on assets −20% · Bottom 25%
Operating margin (TTM) 0% · Below median

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/B 11.35× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Veeva Systems Inc VEEV $270.75 $297.83 +10%
Pro Medicus Limited PME A$161.31 A$64.50 −60%
BrightSpring Health Services, Inc BTSG $56.55 $26.07 −54%
HealthEquity, Inc HQY $91.75 $100.93 +10%
Hinge Health, Inc HNGE $94.15 $51.66 −45%
10x Genomics, Inc TXG $80.70 $21.71 −73%
Waystar Holding WAY $25.63 $28.19 +10%
XtalPi Holdings 2228 HK$8.39 HK$1.50 −82%
Doximity, Inc DOCS $26.51 $31.41 +18%
Privia Health Group PRVA $19.46 $5.26 −73%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

nDatalyze Corp · Fair Value
$0.0240 −233%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "nDatalyze Corp Fair Value". https://www.fairvalue-calculator.com/stock/NDATF

Frequently asked questions

Is nDatalyze Corp (NDATF) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $0.0240 versus the last price from Sep 18, 2026 of $0.0800, about −70% upside (overvalued).
What is the fair value of NDATF?
Our model-based fair value for nDatalyze Corp is $0.0240 (as of Sep 23, 2026), built from audited fundamentals. Last price (from Sep 18, 2026): $0.0800.
What is the quality score of NDATF?
nDatalyze Corp has a Quality Score of 41/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for nDatalyze Corp (NDATF)?
Our model-based price target is the fair value of $0.0240 (as of Sep 23, 2026) from 1 valuation models. It is a calculation from audited fundamentals, not an analyst target.
What is the nDatalyze Corp stock forecast for 2026?
Our models put fair value at $0.0240, about −70% upside versus the last price from Sep 18, 2026 of $0.0800 (overvalued). The calculation is refreshed regularly with new filings.
What is the intrinsic value of nDatalyze Corp (NDATF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For nDatalyze Corp it is $0.0240 per share (as of Sep 23, 2026), against a price of $0.0800. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is nDatalyze Corp stock overvalued or undervalued in 2026?
As of Sep 23, 2026, NDATF trades above its calculated fair value: price $0.0800, fair value $0.0240, a gap of about −70% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of NDATF?
No. The price is what the market pays today ($0.0800); the fair value is what the company's own numbers justify ($0.0240). For nDatalyze Corp the two are $0.0560 per share apart. That gap is exactly why we show both numbers side by side.
How much is nDatalyze Corp worth?
The market values nDatalyze Corp at about $6.1M (market capitalisation, as of Sep 23, 2026). Per share that is $0.0800; our models calculate a fair value of $0.0240 per share.
How solid is the balance sheet of nDatalyze Corp (NDATF)?
Balance-sheet figures for nDatalyze Corp (as of Sep 23, 2026): return on equity −59.8%. They feed the Quality Score of 41/100, which measures business quality independently of the share price.
How far is NDATF from its 52-week high?
nDatalyze Corp trades at $0.0800, at its 52-week high of $0.0800 and 634% above the low of $0.0109 (as of Sep 18, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0240 is for.
Which stocks are comparable to nDatalyze Corp?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, HealthEquity, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is nDatalyze Corp stock attractive at the current price?
The data as of Sep 23, 2026: price $0.0800, calculated fair value $0.0240 (−70%), Quality Score 41/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of NDATF calculated?
We run nDatalyze Corp through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0240, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.0 % above its aggregate fair value. nDatalyze Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of nDatalyze Corp (NDATF)?
The latest price we hold is from Sep 18, 2026 and stands at $0.0800. Our model-based fair value is $0.0240, about −70% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with nDatalyze Corp right now?
The price sits above even our optimistic bull case ($0.0240). The favourable scenario is already priced in. Weak quality (41/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of nDatalyze Corp

How large is the market capitalisation of nDatalyze Corp (NDATF)?
The market capitalisation of nDatalyze Corp is $6.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the return on equity of nDatalyze Corp (NDATF)?
The return on equity (ROE) of nDatalyze Corp is −59.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of nDatalyze Corp (NDATF)?
On an EBIT basis the return on assets of nDatalyze Corp is −79.3% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does nDatalyze Corp (NDATF) generate?
The free cash flow of nDatalyze Corp is −C$466K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does nDatalyze Corp (NDATF) hold?
nDatalyze Corp holds more cash than debt, C$794K net (fiscal year 2024). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch nDatalyze Corp in the live analysis

One click puts nDatalyze Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.